Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.
about
Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort studyAntidepressants and benzodiazepines for panic disorder in adultsAzapirones versus placebo for panic disorder in adultsPsychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adultsDrug therapy for symptoms associated with anxiety in adult palliative care patientsBenzodiazepines versus placebo for panic disorder in adultsAntidepressants versus placebo for panic disorder in adultsAzapirones versus placebo for panic disorder in adultsInterventions for treating anxiety after strokeInterventions for treating anxiety after strokeAugmentation of psychotherapy with d-cycloserine for anxiety disordersPharmacotherapy for anxiety disorders and comorbid alcohol dependencyPharmacotherapy augmentation strategies in treatment-resistant anxiety disordersNewer anticonvulsants in the treatment of anxiety disordersCurrent perspectives on Internet-delivered cognitive behavioral therapy for adults with anxiety and related disordersDrug treatment of obsessive-compulsive disorderThe diagnosis of and treatment recommendations for anxiety disordersAn animal model of panic vulnerability with chronic disinhibition of the dorsomedial/perifornical hypothalamusEtiology, triggers and neurochemical circuits associated with unexpected, expected, and laboratory-induced panic attacksAcute Treatment with a Novel TRPC4/C5 Channel Inhibitor Produces Antidepressant and Anxiolytic-Like Effects in MiceExercise as Treatment for Anxiety: Systematic Review and Analysis.Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effectsThe evidence-based pharmacotherapy of social anxiety disorderEfficacy of the novel antidepressant agomelatine for anxiety symptoms in major depressionGABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.Posttraumatic stress disorder (PTSD) in the German Armed Forces: a retrospective study in inpatients of a German army hospitalAcute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice.Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxietyTwo-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study.Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder.Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation.A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders.Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats?Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.Sub-threshold depression and antidepressants use in a community sample: searching anxiety and finding bipolar disorder.Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort studyBritish Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
P2860
Q21260318-922C2E77-6360-4174-A393-1AF1768F0CFAQ24187763-2CAFEA33-19A7-4A30-8752-C181A13B7DC1Q24193425-6251C2BF-73AE-4C58-8825-C1F038257F53Q24195085-DA741518-2B4C-4B63-9E7A-9282BB339AE8Q24198179-6B66760A-2EBB-4E3E-90AD-2D1341785B63Q24201464-5BA468AF-714C-4CD8-8941-B21FA616844AQ24201481-F346EC7A-6970-4FEF-A5F7-4EC9126C65E5Q24202655-8C5F0E82-0388-49A7-9D4A-61D55AEFA620Q24234175-A3CF64C1-B65F-4231-BF82-47EE6C9F4E47Q24235920-0BE30CB5-6890-4A7D-9A5E-6711305CE3A1Q24240358-78940FFB-76D5-4D63-A98F-778DF265ECA9Q24242257-2ACF1EB7-C0E7-4808-BF1C-396C70147697Q24243827-48357314-932D-4A5C-B8BD-9DA86DBFB703Q24244717-55FD5C8E-15E5-49F5-8F0E-C598D9CABB9CQ24609053-B0899871-14A7-4E63-9BD7-5C5CF00349D4Q24635508-3DA526BC-75BB-4C96-92AC-8F2809081967Q27001768-F73F7405-3EA5-4F29-B88A-39EB33297E0FQ27008085-6F584C50-85B3-4021-A0E7-5363CF2F7B7CQ27026213-9BD2426E-265A-4CE8-824D-F3FA5D072D48Q27322385-009F97F1-D13D-4634-A433-5DBB927DB777Q27693304-C2A2E8ED-9E88-4976-8B80-DA3B78F7F513Q28249253-2B688448-86A0-45A9-AF49-8C7143F5FE8DQ28262456-43705A70-5CAF-4C62-9C15-43E0A22F455EQ28287875-EF98B0BA-6F22-4521-9DCB-B4A9B8CA9EFAQ30421260-4AD28B03-7755-4AD0-883B-0F84C117F2E9Q30463954-2DC2B219-08ED-459D-ABAD-E9981CC61BB0Q30467213-9116F0BB-A0AF-4C1E-89D9-3636A03C8A99Q30477934-5E9E476A-F2E0-42C7-92E3-D3BD90AD0FCBQ30491012-D372A3A7-3EE1-47F3-B2BF-5179C2E770BCQ33487468-F88E0689-086B-408F-8311-11E9847B6287Q33688119-6BBDE0FE-B4A5-4BC8-834B-9CAE418EB1A7Q33780634-26414D7D-1186-406B-A4D2-C1938D13D6C6Q33788380-F3707964-302B-47F1-8C8D-1D5E48FC8B4EQ33810376-0DFD7F13-B776-4A7D-9FD0-D2663747072AQ34024109-349A97AA-CA68-4AC3-AEE9-1DB798AE93D8Q34045126-BC0A4B22-1CB6-4648-B8E5-226C4BB03EA6Q34092254-2E4D7154-978F-41D5-A920-46C5F31249B3Q34094392-AD576975-BFA0-4756-BDA7-2B7472B91783Q34135759-BFF1247D-DC6A-41C8-8E95-DD57B82DD71BQ34183517-508BDA0E-5374-46FD-ACC8-DE3864FC320C
P2860
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Evidence-based guidelines for ...... iation for Psychopharmacology.
@ast
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
Evidence-based guidelines for ...... iation for Psychopharmacology.
@nl
type
label
Evidence-based guidelines for ...... iation for Psychopharmacology.
@ast
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
Evidence-based guidelines for ...... iation for Psychopharmacology.
@nl
prefLabel
Evidence-based guidelines for ...... iation for Psychopharmacology.
@ast
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
Evidence-based guidelines for ...... iation for Psychopharmacology.
@nl
P2093
P2860
P50
P356
P1476
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
P2093
British Association for Psychopharmacology
David S Baldwin
H-U Wittchen
J A den Boer
Jonathan R T Davidson
Naomi A Fineberg
P2860
P304
P356
10.1177/0269881105059253
P407
P577
2005-11-01T00:00:00Z